ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2024
Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies.
Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of continuous glucose monitoring in non-intensively managed type 2 diabetes: a Saudi Arabian consensus.Frontiers in endocrinology · 2025Guideline
- Effect of EEG-guided opioid-free anesthesia on perioperative blood glucose variation in patients undergoing video-assisted thoracic surgery: a secondary analysis of a randomized controlled study.Perioperative medicine (London, England) · 2026Article
- A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics.Frontiers in toxicology · 2026Article
- A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system.Frontiers in medicine · 2026Article
- Sodium-glucose transport 2 inhibitors: Practical management of the venetoclax-induced adverse events.Caspian journal of internal medicine · 2026Article
- Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review.Frontiers in clinical diabetes and healthcare · 2026Review
- Protective role of aqueousFrontiers in endocrinology · 2026Article
- Steroid-Induced Hyperglycaemia in a Patient With Possible Body Dissatisfaction: A Case Report.Cureus · 2025Article
- Etiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients: A Retrospective Analysis.Cancers · 2025Article
- The pathophysiology, presentation and classification of Type 1 diabetes.Diabetes, obesity & metabolism · 2025Review
- Stem cell-derived pancreatic beta cells: a step closer to functional diabetes treatment?BMC endocrine disorders · 2025Review
- Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.Drugs & aging · 2025Review
- Monolayer whole adherent islets: A novel tool for studying drug-induced diabetic phenotypes in vitro.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing global incidence of diabetes mellitus, physicians may encounter more patients with acute and chronic complications of medication-induced hyperglycemia and diabetes. Moreover, medication-induced diabetes may be an important contributing factor to the high rates of diabetes, and recognizing its impact and risk is a critical step in curtailing its effect on the global population. It has long been recognized that multiple classes of medications are associated with hyperglycemia through various mechanisms, and the ability to foresee this and implement adequate management strategies are important. Moreover, different antihyperglycemic medications are better suited to combat the hyperglycemia encountered with different classes of medications, so it is critical that physicians can recognize which agents should be used, and which medications to avoid in certain types of medication-induced hyperglycemia. In this review, we will discuss the evidence behind the main classes of medications that cause hyperglycemia, their mechanism of action, specific agents that are associated with worsened glycemic control, and, most importantly, management strategies that are tailored to each specific class.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.